Table 2.
Epidemiologic and economic results
| Patients | Pazopanib | Sunitinib | Difference | Percent | |
|---|---|---|---|---|---|
| Per patient and cycle pharmacological costs |
|
€4,046 |
€4,904 |
-€858 |
-17.50% |
| Per patient annual (8 cycles) pharmacological costs |
|
€32,365 |
€39,232 |
-€6,867 |
-17.50% |
| Per patient annual costs associated with AE management |
|
€662 |
€974 |
-€312 |
-32.03% |
| Per patient overall annual costs |
|
€33,027 |
€40,206 |
-€7,179 |
-17.85% |
|
Year 2013 |
|
|
|
|
|
| Advanced RCC at diagnosis |
854 |
|
|
|
|
| Progressions to advanced RCC |
934 |
|
|
|
|
| Advanced RCC (favorable or intermediate risk) |
1,591 |
|
|
|
|
| Pharmacological costs |
|
€29,350,968 |
€35,578,198 |
-€6,227,230 |
-17.50% |
| Overall costs |
|
€30,404,210 |
€37,127,832 |
-€6,723,622 |
-18.11% |
|
Year 2014 |
|
|
|
|
|
| Advanced RCC at diagnosis |
866 |
|
|
|
|
| Progressions to advanced RCC |
948 |
|
|
|
|
| Advanced RCC (favorable or intermediate risk) |
1,615 |
|
|
|
|
| Pharmacological costs |
|
€28,925,945 |
€35,063,000 |
-€6,137,056 |
-17.50% |
| Overall costs |
|
€29,963,935 |
€36,590,195 |
-€6,626,260 |
-18.11% |
|
Year 2015 |
|
|
|
|
|
| Advanced RCC at diagnosis |
878 |
|
|
|
|
| Progressions to advanced RCC |
962 |
|
|
|
|
| Advanced RCC (favorable or intermediate risk) |
1,638 |
|
|
|
|
| Pharmacological costs |
|
€28,483,391 |
€34,526,553 |
-€6,043,162 |
-17.50% |
| Overall costs | €29,505,501 | €36,030,382 | -€6,524,881 | -18.11% |